Edwards Lifesciences Corp. (EW) has significantly
outperformed competitors on strong trading days multiple times, only underperforming a few times. The company is considered a
worthy investment. Several institutions, including
Brookstone Capital Management and
AMF Tjanstepension AB, have noted shifts in their Holdings. The fair value of the company has been highlighted, with
the stock's growth driving it towards a 52-week high. It has consistently beaten earnings and revenue estimates, reporting robust Q4 results. The company has also been approved for a
spin-off of its Critical Care Unit in 2024, and recently had a significant stock buyback. Their Q1 2024 earnings call transcript reinforces their growth while their balance sheet has been deemed healthy. Investment Advisers have made major plays in the company. Recently, there was a
complaint of EU antitrust against EW by
Meril. In a major move,
BD is set to acquire EW's Critical Care business for $4.2B. The company beat Q1 earnings estimates due to strength in heart devices and is considered a
likely buy for now.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Sun, 30 Jun 2024 18:00:45 GMT -
Rating 7
- Innovation 7
- Information 8
- Rumor 5
